A Supramolecular Nitric Oxide Nanodelivery System for Prevention of Tumor Metastasis by Inhibiting Platelet Activation and Aggregation
Source abstract
Abstract
Tumor cell-induced platelet aggregation (TCIPA) is known as a critical step in hematogenous tumor metastasis. The endogenous nitric oxide (NO) plays an important role in anticoagulation, which might have great potential to inhibit TCIPA. Herein, a glutathione-sensitive supramolecular nanocarrier is prepared via host–guest interaction for effective delivery of NO and chemotherapeutic agent gemcitabine (GEM). NO could be effectively released in tumor cells and inhibits platelet activation and aggregation. The inhibition of TCIPA by NO could effectively attenuate the migration and invasion of tumor cells in vitro. Furthermore, the in vivo experiments demonstrate that the NO and GEM co-delivered supramolecular nanocarriers can suppress the growth of primary tumor. More importantly, although NO-containing nanocarriers cannot inhibit the growth of primary tumors effectively, they can significantly inhibit tumor metastasis. This NO-based nano-delivery system not only provides new inspiration for multifunctional applications of NO in cancer therapy but also shows great potential in clinical antimetastatic applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inflammatory Biomarkers in Disease Prognosis · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, Zhejiang310027, P. R. China
Funding
Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China
References (57)
Show source-provided references
1. 10.1016/j.cell.2011.09.02410.1016/j.cell.2011.09.024 ↗
2. 10.1136/bmjopen-2017-01602210.1136/bmjopen-2017-016022 ↗
3. 10.1126/science.120354310.1126/science.1203543 ↗
4. 10.1021/acsami.8b0937610.1021/acsami.8b09376 ↗
5. 10.1038/nature1703810.1038/nature17038 ↗
6. 10.3892/or.2016.518410.3892/or.2016.5184 ↗
7. 10.1016/j.ccr.2011.09.00910.1016/j.ccr.2011.09.009 ↗
8. 10.1038/nrc300410.1038/nrc3004 ↗
9. 10.1007/s12282-012-0334-510.1007/s12282-012-0334-5 ↗
10. 10.1345/aph.1H62110.1345/aph.1H621 ↗
11. 10.1016/j.cell.2016.11.03710.1016/j.cell.2016.11.037 ↗
12. 10.1016/S0140-6736(12)60209-810.1016/S0140-6736(12)60209-8 ↗
13. 10.1592/phco.20.4.318.3488110.1592/phco.20.4.318.34881 ↗
14. 10.1038/nrcardio.2017.22410.1038/nrcardio.2017.224 ↗
15. 10.1038/s41581-021-00429-z10.1038/s41581-021-00429-z ↗
16. 10.7326/0003-4819-120-3-199402010-0000910.7326/0003-4819-120-3-199402010-00009 ↗
17. 10.1016/j.biomaterials.2018.09.04310.1016/j.biomaterials.2018.09.043 ↗
18. 10.1161/01.CIR.0000126837.88743.DD10.1161/01.CIR.0000126837.88743.DD ↗
19. 10.1039/C8QM00013A10.1039/C8QM00013A ↗
20. 10.1016/j.biomaterials.2020.11999910.1016/j.biomaterials.2020.119999 ↗
21. 10.1021/acsnano.1c0069810.1021/acsnano.1c00698 ↗
22. 10.1021/acsami.2c1009810.1021/acsami.2c10098 ↗
23. 10.1016/j.bcp.2019.05.03010.1016/j.bcp.2019.05.030 ↗
24. 10.1073/pnas.95.9.488810.1073/pnas.95.9.4888 ↗
25. 10.1002/admi.20140001210.1002/admi.201400012 ↗
26. 10.1021/acsami.1c1096410.1021/acsami.1c10964 ↗
27. 10.1016/j.bioactmat.2022.03.01310.1016/j.bioactmat.2022.03.013 ↗
28. 10.1016/j.polymer.2014.12.02010.1016/j.polymer.2014.12.020 ↗
29. 10.1039/C5RA13341F10.1039/C5RA13341F ↗
30. 10.3390/bioengineering701000910.3390/bioengineering7010009 ↗
31. 10.1002/smll.20120045810.1002/smll.201200458 ↗
32. 10.1002/ppsc.20170028110.1002/ppsc.201700281 ↗
33. 10.1002/smll.20200174710.1002/smll.202001747 ↗
34. 10.1021/acs.bioconjchem.8b0073510.1021/acs.bioconjchem.8b00735 ↗
35. 10.1016/j.cclet.2022.06.01510.1016/j.cclet.2022.06.015 ↗
36. 10.1021/acsnano.8b0774610.1021/acsnano.8b07746 ↗
37. 10.1002/wnan.169110.1002/wnan.1691 ↗
38. 10.1016/j.nantod.2019.10080010.1016/j.nantod.2019.100800 ↗
39. 10.1063/5.006153010.1063/5.0061530 ↗
40. 10.1021/cr500081p10.1021/cr500081p ↗
41. 10.1002/adfm.20190904910.1002/adfm.201909049 ↗
42. 10.1093/annonc/mdj97510.1093/annonc/mdj975 ↗
43. 10.1016/j.ijpharm.2018.08.03710.1016/j.ijpharm.2018.08.037 ↗
44. 10.1021/acsnano.0c0135010.1021/acsnano.0c01350 ↗
45. 10.1021/ma00212a03910.1021/ma00212a039 ↗
46. 10.1021/cr970027+10.1021/cr970027+ ↗
47. 10.1016/0014-5793(85)80758-410.1016/0014-5793(85)80758-4 ↗
48. 10.1038/2121544a010.1038/2121544a0 ↗
49. 10.1093/carcin/bgt03410.1093/carcin/bgt034 ↗
50. 10.1007/s10585-012-9464-610.1007/s10585-012-9464-6 ↗
51. 10.1002/cncr.1091610.1002/cncr.10916 ↗
52. 10.1360/03wc059410.1360/03wc0594 ↗
53. Jurasz P. · Cancer Res. · 2001 · 61 · 376
54. 10.1021/acsnano.0c0219710.1021/acsnano.0c02197 ↗
55. 10.1021/acsnano.6b0554110.1021/acsnano.6b05541 ↗
56. 10.1021/jacs.0c0065010.1021/jacs.0c00650 ↗
57. 10.1002/advs.20220043510.1002/advs.202200435 ↗